Acetylation markers are also gaining traction as predictors of therapy response, high HDAC1 expression is significantly associated with poor lung cancer differentiation, squamous cell carcinoma subtype, and unfavorable patient prognosis, suggesting its potential as a diagnostic and prognostic marker (117). Here, HDAC1 is linked to lung cancer.